Emmy Awards ratings up 8% with CBS audience of 7.4 million

posted in: All news | 0

By ANDREW DALTON, Associated Press

LOS ANGELES (AP) — Ratings for the Emmy Awards have continued their climb from all-time lows as the television industry looks to shake off the shake-ups of recent years.

About 7.42 million viewers tuned in to watch the Nate Bargatze-hosted 77th Primetime Emmy Awards on CBS, according to Nielsen company data released Monday by the network. The night’s big winners were “The Studio,” “Adolescence” and “The Pitt” and a huge outpouring of support for late-night host Stephen Colbert.

It was the most-watched Emmys telecast since 2021, and was up 8% from the 6.87 million that watched the “Shogun”-dominated ABC telecast in September 2024.

Sunday’s show was up more than 70% from the -time low of 4.3 million from the Fox telecast of January 2024, which was delayed by months because of Hollywood’s writers and actors strikes.

Related Articles


Theater review: CTC’s ‘Treasure Island’ well done, but the wrong play for right now


Emmy Awards 2025: Full list of top winners


‘The Pitt’ wins drama Emmy Award as the ‘The Studio’ breaks Emmys comedy record


Photos: 2025 Emmy Awards red carpet standout fashion moments


How to watch tonight’s 2025 Emmy Awards

The pandemic brought its own all-time low. The Emmys in 2020 on ABC, with no in-person audience and remote nominees attracted 6.1 million viewers. The show bounced back the following year with 7.4 million for CBS with help from an NFL game lead-in.

But NBC’s 2022 telecast dropped to 5.9 million, followed by the further dip in early 2024.

The Emmys telecast rotates annually between the four broadcast networks.

The last Emmys to reach more than 10 million viewers was 2018, when it drew in 10.2 million. The show had nearly 22 million viewers in 2000, a level it’s unlikely ever to hit again.

Timberwolves re-sign Bones Hyland

posted in: All news | 0

Bones Hyland will be back with the Timberwolves this season after agreeing to a deal, the team announced Monday.

The reserve guard signed with Minnesota as a two-way player after he was waived by the Clippers in the middle of the 2024-25 campaign.

Hyland helps out round the Timberwolves’ guard depth, where there are question marks behind veteran floor general Mike Conley. Hyland appeared in just four games for the Timberwolves after signing with the team in late February, but he did average 33.5 points in two games with the G-League Wolves.

Hyland has a history with Timberwolves basketball boss Tim Connelly, who drafted the guard when Connelly was in Denver.

 

Kennedy’s vaccine committee plans to vote on COVID-19, hepatitis B and chickenpox shots

posted in: All news | 0

By MIKE STOBBE, Associated Press

NEW YORK (AP) — Health Secretary Robert F. Kennedy Jr.’s new vaccine advisory committee meets this week, with votes expected on whether to change recommendations on shots against COVID-19, hepatitis B and chickenpox.

The exact questions to be voted on Thursday and Friday in Atlanta are unclear. Officials at the Department of Health and Human Services did not immediately respond to questions seeking details to a newly posted agenda.

But some public health experts are worried that the votes will — at a minimum — raise unwarranted new questions about vaccines in the minds of parents.

Perhaps even more consequential would be a vote that restricts a government program from paying for vaccines for low-income families.

“I’m tightening my seat belt,” said Dr. William Schaffner, a Vanderbilt University vaccines expert.

The panel, the Advisory Committee on Immunization Practices, makes recommendations to the director of the Centers for Disease Control and Prevention on how already-approved vaccines should be used. CDC directors have almost always accepted those recommendations, which are widely heeded by doctors and guide vaccination programs.

Kennedy, a leading antivaccine activist before becoming the nation’s top health official, fired the entire 17-member panel earlier this year and replaced it with a group that includes several anti-vaccine voices.

Here’s a look at the three vaccines being discussed:

COVID-19

Before Kennedy was health secretary, ACIP would typically vote in June to reaffirm recommendations for shots against respiratory viruses that sicken millions of Americans each fall and winter.

This past June, Kennedy’s ACIP voted to recommend flu shots for Americans but was silent on COVID-19 shots.

Before that meeting, Kennedy announced he was removing COVID-19 shots from the CDC’s recommendations for healthy children and pregnant women. The move was heavily criticized by doctors’ groups and public health organizations, and prompted a lawsuit by the American Academy of Pediatrics and other groups.

Days after Kennedy’s announcement, CDC officials said families could still get the 2024-2025 version of COVID-19 shots for their kids in consultation with their doctors. That clarification meant shots would still be covered by the federal government’s Vaccines For Children program, which pays for shots for families who lack money or adequate health insurance coverage. It’s now responsible for roughly half of childhood vaccinations in the U.S. each year.

As with flu shots, however, there are new COVID-19 formulations each fall, to account for changes in which strains are circulating. The committee has not yet voted on whether to recommend this season’s COVID-19 shots or whether those shots should be covered by the VFC program.

Further complicating the picture: When the FDA last month licensed this fall’s COVID-19 shots, the agency took the unusual step of narrowing their use for healthy younger adults and children.

If the ACIP simply follows that, and if there is no additional clarifying language from the CDC, then “that would take away access for roughly half of America’s kids,” said Dr. Sean O’Leary of the American Academy of Pediatrics.

The pediatricians group urges that vaccinations continue for all children ages 6 months to 2 years.

FILE – The campus of Centers for Disease Control and Prevention is seen in Atlanta, on Wednesday, June 25, 2025. (AP Photo/Mike Stewart, File)

Hepatitis B

Hepatitis B can cause serious liver infections. In adults, the virus is spread through sex or through sharing needles during use injection-drug use.

But the virus also can be passed to a baby from an infected mother, and as many as 90% of infected infants go on to have chronic infections.

A hepatitis B vaccine was first licensed in the U.S. in 1981. In 1991, the ACIP recommended a dose within 24 hours of birth for all medically stable infants who weigh at least 4.4 pounds.

Infant vaccinations are stressed for women who have hepatitis B or, crucially, who have not been tested for it. The infant shots are 85% to 95% effective in preventing chronic hepatitis B infections, studies have shown.

Newborn hepatitis B vaccinations are considered a success, and no recent peer-reviewed research shows any safety problem with giving kids the shots on their first day of life, Schaffner said.

But Kennedy’s ACIP members suggested in June they wanted to revisit the guidance.

Schaffner noted that health officials used to rely on screening mothers before birth but that many cases were missed.

“There were lots of failures,” he said. “And so there were continuing transmissions from mother to child.”

Related Articles


Trump threatens to take over DC police again over immigration enforcement


Vance hosts Kirk’s radio show and says he’ll honor his friend by being a better husband and father


Fired federal prosecutor Maurene Comey sues Trump administration to get her job back


Trump administration boosts HBCU funding after cutting grants for Hispanic-serving colleges


Annual Hispanic Heritage Month celebrations make adjustments in current political climate

MMRV

Chickenpox was once a common childhood annoyance, causing an itchy skin rash and fever.

But the highly contagious virus can also lead to complications such as skin infections, swelling of the brain and pneumonia. Severe cases are more common among teens and adults who get it for the first time. The virus — called varicella — also can reactivate later in life and cause the painful illness called shingles.

The government first recommended that all children get a chickenpox vaccine in 1995, leading to a dramatic drop in cases and deaths.

In 2006, a combination MMRV shot — measles, mumps, rubella and varicella — was licensed. The CDC initially recommended that doctors and parents use the combo shot over separate MMR and varicella injections.

But within a few years, studies showed children who got the combo shot more often developed a rash, fever and — in rare instances — seizures after vaccination compared with children who got separate shots.

In 2009, the ACIP changed its recommendation, removing the preferential language and saying either the combination shot or separate shots were acceptable for the first dose.

Today, most pediatricians suggest separate doses for the first shot, but give the combined shot for the second dose, pediatrics experts say.

Again, there’s no new evidence about harms from MMRV shots, said O’Leary, of AAP.

Why revisit it now?

“This version of the ACIP is an orchestrated effort to sow distrust in vaccines,” O’Leary said.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

High AAV, fewer years, might be right for Kirill Kaprizov — and Wild

posted in: All news | 0

In September 2024, Wild owner Craig Leipold vowed that no NHL team would offer star forward Kirill Kaprizov more money or more years than Minnesota. Leipold proved to be a man of his word this month as the Wild reportedly offered the Russian scoring machine the largest contract in NHL history.

A week later, with training camp just days away, Kaprizov hasn’t taken Leipold on that eight-year, $128 million. With neither the Wild nor the player’s agent, Paul Theofanous, talking about why or what’s next, speculation is running at a fever pitch.

Minnesota Wild left wing Kirill Kaprizov (97) skates on the ice during the first period of an NHL hockey game against the Calgary Flames, Saturday, Jan. 25, 2025, in St. Paul, Minn. (AP Photo/Ellen Schmidt)

Has another team, against NHL rules, made it clear to Theofanous and Kaprizov that there’s even more money available if they hold out for unrestricted free agency next July? Does Kaprizov want out of Minnesota? Does Kaprizov want even more money?

Many Wild fans, generally speaking, are worried that after a glimpse of life with a superstar, it’s all going to end in less than a year. Among those who aren’t concerned, seemingly, are Kaprizov and his Wild teammates.

“He’s got another year, he wants to play the game, and he doesn’t get phased by that stuff,” Wild forward Marcus Foligno said Monday at the team’s charity golf outing in Lake Elmo. “It’s going to take time. There’s just little things that they need to go back and forth with. We’re positive that he’ll be around, and knowing Kirill, he’s just focused on the next game and how to win as a team this season.”

As we wait for the next phase of the “back and forth,” one retired former NHL front office executive, speaking to the Pioneer Press on background, offered a theory that makes some sense: Perhaps the Wild’s initial offer was too light on money and too heavy on years.

Kaprizov is coming off the shortest campaign of a five-year NHL career, 41 regular-season games after suffering a lower body injury that required surgery after the New Year. He still finished second on the team in goals (25), third in assists (31) and third in points (56).

The generally-accepted thinking is that a player dealing with injuries will want to get the largest number of years available in his next contract to secure his financial future, regardless of his health and durability over the next few seasons. But confident athletes in the prime of their playing years tend to bet on themselves, determined that their production will continue at the levels they, and their teams, have come to expect.

Kaprizov turned 28 in April, in the midst of the Wild’s first-round playoff series versus Vegas. Minnesota’s top-line winger put on a show, scoring five goals in the six games. If he agreed to the Wild’s first offer, and signed here for another eight years, that would make him 36 (or 37 depending on when the new contract officially began) when he was next a free agent.

A player that age can see the finish line to his playing career. So can teams that might sign him, which would be reflected in the offers he gets. By contrast, if Kaprizov’s next contract is shorter — four to six years for, say, $18 million a year — he would be around 34 when seeking what likely would be his final pro contract.

At that point, teams would expect more out of him, and pay him more as he skates into the sunset.

A shorter-term contract also would likely allay the fears of some Wild fans, who felt burned by 13-year deals that Zach Parise and Ryan Suter signed in 2012. Bought out with four years remaining on their deals, both are still being paid by the Wild through next season, and the buyout terms ate up large chunks of the team’s cap space for the two seasons.

While having Kaprizov under contract for the next two election cycles sounds good to some, the mammoth Parise and Suter deals seemed like a winning play at the time, as well.

The Wild promised to make Kaprizov an offer bigger than anyone had ever seen before, and kept their word. He reportedly wants something different. While there is surely much to come in this ongoing story — training camp officially begins Thursday at TRIA Rink — tweaking the offer to include more money for fewer seasons makes sense.

Related Articles


In-season trade an iffy option if Wild, Kirill Kaprizov reach impasse


Shipley: Not a great start to the Kirill Kaprizov negotiations


Report: Kirill Kaprizov rejects NHL-record offer from Wild


Wild owner prepared to give Kirill Kaprizov a record NHL deal


Former Wild star Zach Parise selected for US Hockey Hall of Fame